Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Cyclerion Therapeutics, Inc. Regina Graul, Ph.D., Promoted to Chief Executive Officer August 07, 2024 From Cyclerion Therapeutics, Inc. Via GlobeNewswire Tickers CYCN Cyclerion Appoints Regina Graul, Ph.D., as President December 04, 2023 From Cyclerion Therapeutics, Inc. Via GlobeNewswire Tickers CYCN Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator November 30, 2023 From Cyclerion Therapeutics, Inc. Via GlobeNewswire Tickers CYCN Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets July 31, 2023 From Cyclerion Therapeutics, Inc. Via GlobeNewswire Tickers CYCN Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement June 01, 2023 From Cyclerion Therapeutics, Inc. Via GlobeNewswire Tickers CYCN Cyclerion Announces Reverse Stock Split May 15, 2023 From Cyclerion Therapeutics, Inc. Via GlobeNewswire Tickers CYCN Cyclerion Announces Corporate Updates and Q1 2023 Financial Results May 11, 2023 From Cyclerion Therapeutics, Inc. Via GlobeNewswire Tickers CYCN Cyclerion Announces Definitive Agreement for Zagociguat and CY3018 May 11, 2023 From Cyclerion Therapeutics, Inc. Via GlobeNewswire Tickers CYCN Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement April 03, 2023 From Cyclerion Therapeutics, Inc. Via GlobeNewswire Tickers CYCN Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases March 27, 2023 From Cyclerion Therapeutics, Inc. Via GlobeNewswire Tickers CYCN Cyclerion Reports Corporate Update and Full Year 2022 Financial Results March 22, 2023 From Cyclerion Therapeutics, Inc. Via GlobeNewswire Tickers CYCN Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company November 22, 2022 From Cyclerion Therapeutics, Inc. Via GlobeNewswire Tickers CYCN Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy October 06, 2022 From Cyclerion Therapeutics, Inc. Via GlobeNewswire Tickers CYCN Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS) July 28, 2022 From Cyclerion Therapeutics, Inc. Via GlobeNewswire Tickers CYCN Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors July 26, 2022 From Cyclerion Therapeutics, Inc. Via GlobeNewswire Tickers CYCN Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
